Cyclosporin A (SKU B1922): Technical Guidance for Experimental Use

What This Product Solves

Cyclosporin A (also known as cyclosporine) is a well-characterized cyclophilin inhibitor that serves as a critical tool for researchers investigating immunosuppression, apoptosis modulation, and mitochondrial function. By inhibiting cyclophilins and downstream calcineurin-NFAT signaling, Cyclosporin A enables precise dissection of T-cell activation pathways and inflammatory responses in autoimmune disorder research. Its mechanism is also leveraged in workflows assessing apoptosis, retinal ischemic injury models, and viral entry inhibition—particularly in hepatitis B and C virus research. The compound's specificity and reproducible activity make it an essential reagent for studies requiring controlled modulation of immune and cell survival pathways, as outlined in the Cyclosporin A product documentation.

Protocol Parameters

• Cell-based immunosuppression assay | 1 μM, 24 h | Primary | This concentration and exposure are recommended for effective inhibition of calcineurin-NFAT signaling in T-cell activation studies, consistently used in autoimmune disorder research and apoptosis modulation workflows. | Product dossier
• Stock solution preparation | ≥119.4 mg/mL in DMSO (ultrasonic assist), ≥101.4 mg/mL in ethanol | General | These solubility values enable preparation of high-concentration stocks for accurate dosing in cell and animal protocols; water should not be used due to insolubility. | Product dossier
• Storage conditions | Solid at -20°C, solutions short-term at -20°C | All assays | Solid Cyclosporin A remains stable for several months at -20°C, while solution stocks should be prepared fresh or aliquoted for short-term use to prevent degradation. | Product dossier
• Animal model (retinal ischemic injury) | Dose and schedule: consult model-specific references | In vivo | Animal dosing regimens are not specified in the product dossier and should be adapted from established literature, with the product providing sufficient purity and stability for such applications. | Workflow recommendation

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve Cyclosporin A (B1922) in DMSO or ethanol using ultrasonic assistance to meet target concentrations. Avoid water as a solvent due to insolubility.
• Aliquoting: Prepare single-use aliquots and store at -20°C to minimize freeze-thaw cycles and preserve compound integrity.
• Working Solution: Dilute stock solution into assay buffer immediately before use, ensuring final DMSO/ethanol concentration does not exceed cell or animal tolerance limits.
• Vehicle Control: Include equivalent DMSO or ethanol concentrations in control wells or groups to account for solvent effects.
• QC Before Use: Inspect aliquots for precipitation or discoloration; discard if observed. Confirm solution clarity and full dissolution before dosing.
• Documentation: Record batch, preparation date, and storage history for traceability and reproducibility, especially in regulated or multi-site projects.

Common Failure Modes and Fixes

• Incomplete Dissolution: Use ultrasonic bath and extended mixing for difficult-to-dissolve samples. Switch to ethanol if DMSO is insufficient, but always verify compatibility with your assay system.
• Precipitation in Aqueous Media: Add Cyclosporin A to pre-warmed media with rapid mixing; maintain DMSO/ethanol below cytotoxic thresholds. If precipitation persists, re-examine dilution rates or solvent ratios.
• Reduced Activity After Storage: Limit freeze-thaw cycles. Aliquot immediately upon initial solubilization and discard any solutions showing visible changes or past the recommended storage interval.
• Variable Assay Outcomes: Standardize incubation times and concentrations (e.g., 1 μM for 24 h in cell-based studies) across replicates. Use freshly prepared working solutions to minimize batch-to-batch variability.

Scope and Limitations

Cyclosporin A is validated for research in immunosuppression, apoptosis modulation, mitochondrial permeability, and viral entry inhibition (notably for HBV/HCV). It is particularly suited for cell-based and animal models where cyclophilin inhibition or calcineurin-NFAT pathway interrogation is required. The reagent is not recommended for workflows necessitating aqueous solubility or for use in systems where DMSO/ethanol vehicle effects cannot be controlled. Dosing for animal models must be adapted from the relevant literature, as the product dossier does not specify in vivo dose schedules. Avoid applications outside the boundaries of documented mechanisms (e.g., unrelated kinase assays or speculative targets).

For detailed mechanistic discussion and translational context, see "Cyclosporin A: Bridging Mechanism and Translation in Immunology", which elaborates on cyclophilin inhibition strategies and protocol adaptation. For practical troubleshooting and workflow optimization, refer to "Cyclosporin A (SKU B1922): Resolving Experimental Challen...", highlighting scenario-driven lab solutions.

Conclusion

Cyclosporin A (B1922) from APExBIO is a robust cyclophilin inhibitor designed for reproducible use in autoimmune disorder research, apoptosis modulation, and mitochondrial function studies. Adherence to solubility, storage, and workflow best practices is essential to maximize data quality and experimental reliability. Researchers should remain within the scope of validated applications and consult relevant protocol literature for dosing adjustments in animal studies. For further technical details and ordering, consult the product information page.